ArticleParasitology research2012
Curcumin treatment provides protection against Trypanosoma cruzi infection.
Article in Parasitology research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents.Acta parasitologica · 2021Pooled it
- Exceeding the Limits with Nutraceuticals: Looking Towards Parkinson's Disease and Frailty.International journal of molecular sciences · 2024Review
- Combination Therapy and Phytochemical-Loaded Nanosytems for the Treatment of Neglected Tropical Diseases.Pharmaceutics · 2024Review
- In vitro and in vivo anti-parasitic activity of curcumin nanoemulsion on Leishmania major (MRHO/IR/75/ER).BMC complementary medicine and therapies · 2024Article
- Theracurmin Modulates Cardiac Inflammation in Experimental Model ofTropical medicine and infectious disease · 2023Article
- Protoscolicidal effects of curcumin nanoemulsion against protoscoleces of Echinococcus granulosus.BMC complementary medicine and therapies · 2023Article
- Curcumin ameliorates chronicIranian journal of basic medical sciences · 2023Article
- Structure-activity relationship of dibenzylideneacetone analogs against the neglected disease pathogen, Trypanosoma brucei.Bioorganic & medicinal chemistry letters · 2023Article
- Protective effects of Theracurmin treatment during experimental infection of the Colombian strain ofFrontiers in cellular and infection microbiology · 2023Article
- Resveratrol and Curcumin for Chagas Disease Treatment-A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The Use of Antioxidants as Potential Co-Adjuvants to Treat Chronic Chagas Disease.Antioxidants (Basel, Switzerland) · 2021Review
- Molecular Targets Implicated in the Antiparasitic and Anti-Inflammatory Activity of the Phytochemical Curcumin in Trichomoniasis.Molecules (Basel, Switzerland) · 2020Article
- In vivo assessment of the antischistosomal activity of curcumin loaded nanoparticles versus praziquantel in the treatment of Schistosoma mansoni.Scientific reports · 2020Article
- Heme oxygenase-1 in protozoan infections: A tale of resistance and disease tolerance.PLoS pathogens · 2020Review
- Potential Role of Antioxidants as Adjunctive Therapy in Chagas Disease.Oxidative medicine and cellular longevity · 2020Review
- Dual and Opposite Roles of Reactive Oxygen Species (ROS) in Chagas Disease: Beneficial on the Pathogen and Harmful on the Host.Oxidative medicine and cellular longevity · 2020Review
- Curcumin exerts anti-inflammatory and vasoprotective effects through amelioration of NFAT-dependent endothelin-1 production in mice with acute Chagas cardiomyopathy.Memorias do Instituto Oswaldo Cruz · 2018Article
- ROS and Trypanosoma cruzi: Fuel to infection, poison to the heart.PLoS pathogens · 2018Review
- Curcumin nanoemulsion as a novel chemical for the treatment of acute and chronic toxoplasmosis in mice.International journal of nanomedicine · 2018Article
- Antiparasitic Efficacy of Curcumin AgainstFrontiers in veterinary science · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Trypanosoma cruzi, the etiologic agent of Chagas disease, causes an acute myocarditis and chronic cardiomyopathy. The current therapeutic agents for this disease are not always effective and often have severe side effects. Curcumin, a plant polyphenol, has demonstrated a wide range of potential therapeutic effects. In this study, we examined the effect of curcumin on T. cruzi infection in vitro and in vivo. Curcumin pretreatment of fibroblasts inhibited parasite invasion. Treatment reduced the expression of the low density lipoprotein receptor, which is involved in T. cruzi host cell invasion. Curcumin treatment of T. cruzi-infected CD1 mice reduced parasitemia and decreased the parasitism of infected heart tissue. This was associated with a significant reduction in macrophage infiltration and inflammation in both the heart and liver; moreover, curcumin-treated infected mice displayed a 100% survival rate in contrast to the 60% survival rate commonly observed in untreated infected mice. These data are consistent with curcumin modulating infection-induced changes in signaling pathways involved in inflammation, oxidative stress, and apoptosis. These data suggest that curcumin and its derivatives could be a suitable drug for the amelioration of chagasic heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.